About Xeris Pharmaceuticals
Xeris Pharmaceuticals is a publicly listed company based in Chicago (United States) founded in 2005 by Steve Prestrelski. Liquid-stable injectables are developed for peptide and protein drug delivery. Xeris Pharmaceuticals has raised $110.43 million across 21 funding rounds from investors including Hayfin, HHS and Epilepsy Foundation. The company has 394 employees. Xeris Pharmaceuticals has completed 1 acquisition, including Strongbridge Biopharma. Its chief executive, as recorded, is Paul Edick. Its website xerispharma.com draws about 12 thousand monthly visits. Its focus areas include Life Sciences, Drug Delivery, Safe Syringes and Auto Injector. Its competitors include Insulet, Companion Medical and Qlibrium; 2 of its 3 listed competitors have raised funding.
Company details
Xeris Pharmaceuticals was founded in 2005 in Chicago, United States, within the biotechnology sector. Liquid-stable injectables are developed for subcutaneous and intramuscular drug delivery. A ready-to-inject glucagon formulation, Gvoke, is indicated for severe hypoglycemia treatment in adult and pediatric diabetic patients. Proprietary XeriSol and XeriJect technologies are applied to create non-aqueous formulations of peptides, proteins, and antibodies.
- Headquarters Chicago, United States
- Employees 394
- Founders Steve Prestrelski
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website xerispharma.com
- Social LinkedIn X
- Legal Name Xeris Biopharma Holdings, Inc.
- Annual Revenue$291.85 M (USD)43.72as on Dec 31, 2025
- Net Profit$554 K (USD)as on Dec 31, 2025
- EBITDA$37.59 M (USD)as on Dec 31, 2025
- Total Equity Funding$110.43M (USD)
in 21 rounds
- InvestorsHayfin
& 15 more
- Employee Count394
- Investments & Acquisitions
Funding Insights of Xeris Pharmaceuticals
Xeris Pharmaceuticals has successfully raised a total of $110.43M across 21 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $110.43M
- Total Rounds 21
- First Round $55,000
(Dec 2005)
- Investors Count 16
Latest 10 of 21 funding rounds of Xeris Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | Post-IPO | – | – | ||
| Mar 2021 | $27M | Post-IPO | – | – | |
| Mar 2018 | $10M | Series C | – | Merieux Equity Partners | |
| May 2017 | $30.05M | Series C | – | Redmile Group | |
| Jan 2016 | $41M | Series C | – | Redmile Group | |
| Sep 2015 | $514,129 | Grant | – | – | |
| Mar 2015 | $485,403 | Grant | – | – | |
| Jan 2015 | $17.9M | Series B | – | – | – |
| Sep 2014 | $7.27M | Series A | – | – | – |
| Feb 2014 | $421,600 | Grant | – | – |
16 investors in total: 16 institutional.
Investors in Xeris Pharmaceuticals
Xeris Pharmaceuticals has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Hayfin, HHS and Epilepsy Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private debt investments are directed across multiple sectors. | 2013 | hayfin.com | London, United Kingdom | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Early-stage tech and life sciences focused family office firm investing in the US | wildbasininv.com | Austin, United States | ||
Pivate equity firm that focuses on investing in healthcare and nutrition companies | merieux-partners.com | Lyon, France | ||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Innovative global companies are supported through venture capital investments by Asahi Kasei Ventures. | 1922 | asahikaseiventures.com | Tokyo, Japan | |
A charitable trust focused on healthcare and research funding. | helmsleytrust.org | New York, United States | ||
Deep tech commercialization is facilitated by Austin Technology Incubator. | 1989 | ati.utexas.edu | Austin, USA | |
| centraltexasangelnetwork.com | ||||
Global hedge fund managing long/short investments in health care and consumer sectors. | 2012 | armisticecapital.com | New York, United States |
Investor details for Xeris Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Xeris Pharmaceuticals
106 people are tracked at Xeris Pharmaceuticals (56 in leadership, 8 in board & advisors, 42 in team); the tracked headcount is 394.
| Name | Role | Group |
|---|---|---|
Steve Prestrelski | Co-Founder & CSO | Leadership |
Paul Edick | CEO & Chairman | Leadership |
Francis M. | VP Of IT | Leadership |
John Shannon | President & COO | Leadership |
Steve Pippin | Director, Device Development | Leadership |
Mathew Rutland | Associate Director Of Training & Development | Leadership |
Steve Pieper | CFO | Leadership |
Kiryl Tsukerman | Director, Business Development And New Product Planning | Leadership |
Margaret Besing | Executive Director, Pharmacovigilance Operations | Leadership |
Bukola O. | Senior Regional Medical Affairs Director | Leadership |
Tapan Patel | Executive Director - Medical Affairs Pipeline Strategy | Leadership |
Laurie Vandeventer | Regional Medical Affairs Director | Leadership |
John Crean | Regional Medical Director | Leadership |
Krista Coleman | Vice President Finance | Leadership |
Aubrey Papaeliou Mba (Barry) | Director Talent Management | Leadership |
Michele Yelmene | Vice President Global Regulatory Affairs & Operations | Leadership |
Eric Lewis | Vice President, Market Access, Pricing & Reimbursement | Leadership |
Vanessa Bassett | Assistant Vice President Sales - Gvoke | Leadership |
Christine Savchenko | Associate Director Commercial Analytics & Reporting | Leadership |
James Meyer Pharmd | Executive Scientific Director | Leadership |
86 more people are available in the full profile.
Complete people profiles for Xeris Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Xeris Pharmaceuticals
Xeris Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol XERS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Jun 2018
- Listed onNASDAQ: XERS
- Listed entityXeris Biopharma Holdings, Inc.
- Exchange sectorHealth technology
- ISINUS98422E1038
- Share price$10.20 (-2.49% on the day) · 2026-10-13
- Market capitalisation$1.86B
- EPS (diluted, trailing year)$-0.10
- Volume (last session)2,220,299
Financials of Xeris Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $291.9M | $554,000 | $37.6M |
| 2024 | $203.1M | -$54.8M | -$21.0M |
| 2023 | $163.9M | -$62.3M | -$30.9M |
| 2022 | $110.2M | -$94.7M | -$67.8M |
| 2021 | $49.6M | -$122.7M | -$103.6M |
Detailed financial statements for Xeris Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xeris Pharmaceuticals
Xeris Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Strongbridge Biopharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drugs for rare endocrine disorders are developed and advanced. | strongbridgebio.com | Feasterville Trevose, United States | 1996 | May 2021 | •••• |
Complete acquisition details for Xeris Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Xeris Pharmaceuticals
5 dated milestones of Xeris Pharmaceuticals across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Xeris Pharmaceuticals is founded.
- Funding First funding round of $55K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Strongbridge Biopharma.
- Funding Latest funding round, Post-IPO,.
Competitors of Xeris Pharmaceuticals
Xeris Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Insulet, Companion Medical and Qlibrium.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insulet.com | 2000 | Boston, United States | $120.4M | 2,600 | Wearable insulin infusion systems are developed for diabetes patients. | |
| companionmedical.com | 2013 | San Diego, United States | $24.09M | Smart insulin pens with Bluetooth smartphone connectivity are developed. | ||
| qlibriumlabs.com | 2014 | Woburn, United States | On-body drug delivery systems are developed using advanced microfluidic technology. |
Detailed competitors of Xeris Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Xeris Pharmaceuticals
The website of Xeris Pharmaceuticals (xerispharma.com) receives about 11.8K visits a month and ranks #2,449,948 among all websites worldwide, #3,352 in Biotechnology and Pharmaceuticals.
- Monthly visits11.8K
▲ 35.2% vs previous month
- Unique visitors3.5K
per month
- Global rank#2,449,948
among all websites
- Category rank#3,352
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.9
- Average visit9 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Xeris Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alkermes.com | 100% | 22.7K | #1,117,011 | View details | |
| xenon-pharma.com | 100% | 19.4K | View details | ||
| takeda.com | 100% | 620.1K | #93,966 | View details | |
astrazeneca-us.com | astrazeneca-us.com | 100% | #659,648 | – | |
| medexus.com | 36% | 6.4K | #3,239,042 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Xeris Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Xeris Pharmaceuticals (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xeris Pharmaceuticals
Complete news archive for Xeris Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xeris Pharmaceuticals
Xeris Pharmaceuticals was founded in 2005.
Xeris Pharmaceuticals is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Paul Edick is the CEO of Xeris Pharmaceuticals, as recorded in our data.
Xeris Pharmaceuticals is a funded company, having raised a total of $110.43M across 21 funding rounds to date. The company's 1st funding round was a Grant of $421.6K, raised on Dec 2005.
Xeris Pharmaceuticals has 394 employees.
Annual revenue of Xeris Pharmaceuticals is $291.85M as on Dec 31, 2025.
Xeris Pharmaceuticals was founded in 2005 in Chicago, United States, within the biotechnology sector. Liquid-stable injectables are developed for subcutaneous and intramuscular drug delivery. A ready-to-inject glucagon formulation, Gvoke, is indicated for severe hypoglycemia treatment in adult and pediatric diabetic patients. Proprietary XeriSol and XeriJect technologies are applied to create non-aqueous formulations of peptides, proteins, and antibodies.
Xeris Pharmaceuticals's top competitors include Insulet, Companion Medical and Qlibrium.
Yes, Xeris Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol XERS.
Xeris Pharmaceuticals has made 1 acquisition, including Strongbridge Biopharma.
Xeris Pharmaceuticals has 16 investors. Key investors include Hayfin, HHS, Epilepsy Foundation, Armistice Capital, and Deerfield.